|
lixisenatide |
|
CHEBI:85662 |
|
A forty-four membered polypeptide consisting of L-His, Gly, L-Glu, Gly, L-Thr, L-Phe, L-Thr, L-Ser, L-Asp, L-Leu, L-Ser, L-Lys, L-Gln, L-Met, L-Glu, L-Glu, L-Glu, L-Ala, L-Val, L-Arg, L-Leu, L-Phe, L-Ile, L-Glu, L-Trp, L-Leu, L-Lys, L-Asn, Gly, Gly, LPro, L-Ser, L-Ser, Gly, L-Ala, L-Pro, L-Pro, L-Ser, L-Lys, L-Lys, L-Lys, L-Lys, L-Lys, and L-Lys-NH2 residues joined in sequence. Used as an adjunct to diet and exercise for the treatment of adults with type II diabetes. |
|
This entity has been manually annotated by the ChEBI Team.
|
|
|
|
Molfile
XML
SDF
|
|
|
|
InChI=1S/C215H347N61O65S/c1-16-115(10)173(210(337)256-141(68-74-170(299)300)194(321)261-148(94-122-98-232-126-50-24-23-49-124(122)126)199(326)258-143(89-111(2)3)196(323)247-134(58-32-40-83-223)189(316)262-149(96-160(226)285)180(307)235-100-161(286)233-104-165(290)274-85-42-60-156(274)207(334)267-154(108-280)206(333)265-151(105-277)181(308)237-101-162(287)239-117(12)213(340)276-87-44-62-158(276)214(341)275-86-43-61-157(275)208(335)268-153(107-279)204(331)249-132(56-30-38-81-221)187(314)246-131(55-29-37-80-220)186(313)245-130(54-28-36-79-219)185(312)244-129(53-27-35-78-218)184(311)243-128(52-26-34-77-217)183(310)242-127(176(227)303)51-25-33-76-216)272-201(328)146(92-120-45-19-17-20-46-120)260-197(324)144(90-112(4)5)257-190(317)135(59-41-84-231-215(228)229)255-209(336)172(114(8)9)271-177(304)116(11)240-182(309)138(65-71-167(293)294)251-192(319)139(66-72-168(295)296)252-193(320)140(67-73-169(297)298)253-195(322)142(75-88-342-15)254-191(318)137(63-69-159(225)284)250-188(315)133(57-31-39-82-222)248-203(330)152(106-278)266-198(325)145(91-113(6)7)259-200(327)150(97-171(301)302)263-205(332)155(109-281)269-212(339)175(119(14)283)273-202(329)147(93-121-47-21-18-22-48-121)264-211(338)174(118(13)282)270-164(289)103-236-179(306)136(64-70-166(291)292)241-163(288)102-234-178(305)125(224)95-123-99-230-110-238-123/h17-24,45-50,98-99,110-119,125,127-158,172-175,232,277-283H,16,25-44,51-97,100-109,216-224H2,1-15H3,(H2,225,284)(H2,226,285)(H2,227,303)(H,230,238)(H,233,286)(H,234,305)(H,235,307)(H,236,306)(H,237,308)(H,239,287)(H,240,309)(H,241,288)(H,242,310)(H,243,311)(H,244,312)(H,245,313)(H,246,314)(H,247,323)(H,248,330)(H,249,331)(H,250,315)(H,251,319)(H,252,320)(H,253,322)(H,254,318)(H,255,336)(H,256,337)(H,257,317)(H,258,326)(H,259,327)(H,260,324)(H,261,321)(H,262,316)(H,263,332)(H,264,338)(H,265,333)(H,266,325)(H,267,334)(H,268,335)(H,269,339)(H,270,289)(H,271,304)(H,272,328)(H,273,329)(H,291,292)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,301,302)(H4,228,229,231)/t115-,116-,117-,118+,119+,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,172-,173-,174-,175-/m0/s1 |
XVVOERDUTLJJHN-IAEQDCLQSA-N |
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O |
|
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
|
|
glucagon-like peptide-1 receptor agonist
An agonist that binds to and activates glucagon-like peptide-1 (GLP-1) receptors.
|
|
neuroprotective agent
Any compound that can be used for the treatment of neurodegenerative disorders.
hypoglycemic agent
A drug which lowers the blood glucose level.
|
|
View more via ChEBI Ontology
L-histidylglycyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-methionyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-valyl-L-arginyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-L-tryptophyl-L-leucyl-L-lysyl-L-asparaginylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-seryl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysinamide
|
lixisenatida
|
WHO MedNet
|
lixisenatide
|
WHO MedNet
|
lixisénatide
|
WHO MedNet
|
lixisenatidum
|
WHO MedNet
|
AQVE-10010
|
ChemIDplus
|
AVE 0010
|
ChemIDplus
|
AVE0010
|
ChemIDplus
|
des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide
|
ChemIDplus
|
DesPro38Exendin-4(1-39)-Lys6-NH2
|
ChemIDplus
|
H-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2
|
ChEBI
|
H-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2
|
ChEBI
|
H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2
|
ChEBI
|
H-L-His-Gly-L-Glu-Gly-L-Thr-L-Phe-L-Thr-L-Ser-L-Asp-L-Leu-L-Ser-L-Lys-L-Gln-L-Met-L-Glu-L-Glu-L-Glu-L-Ala-L-Val-L-Arg-L-Leu-L-Phe-L-Ile-L-Glu-L-Trp-L-Leu-L-Lys-L-Asn-Gly-Gly-L-Pro-L-Ser-L-Ser-Gly-L-Ala-L-Pro-L-Pro-L-Ser-L-Lys-L-Lys-L-Lys-L-Lys-L-Lys-L-Lys-NH2
|
ChEBI
|
ZP 10
|
ChemIDplus
|
ZP10A peptide
|
ChemIDplus
|
Adlyxin
|
ChEBI
|
Lyxumia
|
ChemIDplus
|
23952540
|
Reaxys Registry Number
|
Reaxys
|
320367-13-3
|
CAS Registry Number
|
ChemIDplus
|
19629885
|
PubMed citation
|
Europe PMC
|
21391833
|
PubMed citation
|
Europe PMC
|
23537041
|
PubMed citation
|
Europe PMC
|
23558600
|
PubMed citation
|
Europe PMC
|
23825925
|
PubMed citation
|
Europe PMC
|
23992745
|
PubMed citation
|
Europe PMC
|
24086950
|
PubMed citation
|
Europe PMC
|
24122776
|
PubMed citation
|
Europe PMC
|
24363554
|
PubMed citation
|
Europe PMC
|
24373190
|
PubMed citation
|
Europe PMC
|
24476092
|
PubMed citation
|
Europe PMC
|
24583037
|
PubMed citation
|
Europe PMC
|
24641271
|
PubMed citation
|
Europe PMC
|
24683832
|
PubMed citation
|
Europe PMC
|
24876548
|
PubMed citation
|
Europe PMC
|
25012990
|
PubMed citation
|
Europe PMC
|
25027491
|
PubMed citation
|
Europe PMC
|
25055456
|
PubMed citation
|
Europe PMC
|
25066229
|
PubMed citation
|
Europe PMC
|
25107586
|
PubMed citation
|
Europe PMC
|
25115916
|
PubMed citation
|
Europe PMC
|
25119443
|
PubMed citation
|
Europe PMC
|
25130920
|
PubMed citation
|
Europe PMC
|
25195184
|
PubMed citation
|
Europe PMC
|
25773712
|
PubMed citation
|
Europe PMC
|
25802728
|
PubMed citation
|
Europe PMC
|
25853868
|
PubMed citation
|
Europe PMC
|
25887358
|
PubMed citation
|
Europe PMC
|
25965710
|
PubMed citation
|
Europe PMC
|
26342556
|
PubMed citation
|
Europe PMC
|
26423184
|
PubMed citation
|
Europe PMC
|
26537183
|
PubMed citation
|
Europe PMC
|
26594250
|
PubMed citation
|
Europe PMC
|
26630143
|
PubMed citation
|
Europe PMC
|
26701217
|
PubMed citation
|
Europe PMC
|
26770666
|
PubMed citation
|
Europe PMC
|
26787264
|
PubMed citation
|
Europe PMC
|
26981945
|
PubMed citation
|
Europe PMC
|
26981946
|
PubMed citation
|
Europe PMC
|
26981947
|
PubMed citation
|
Europe PMC
|
27092017
|
PubMed citation
|
Europe PMC
|
27222510
|
PubMed citation
|
Europe PMC
|
27252787
|
PubMed citation
|
Europe PMC
|
27267268
|
PubMed citation
|
Europe PMC
|
27284114
|
PubMed citation
|
Europe PMC
|
27310712
|
PubMed citation
|
Europe PMC
|
27311491
|
PubMed citation
|
Europe PMC
|
27319011
|
PubMed citation
|
Europe PMC
|
27341040
|
PubMed citation
|
Europe PMC
|
|